Neovasc

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neovasc Inc. is a specialty medical device company that develops and manufactures products for the rapidly growing cardiovascular device marketplace.Neovasc Inc. offers pericardial tissue processing, vascular product development, design, and manufacturing solutions to industry partners.

NEW YORK, Nov. 9, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Neovasc Inc. (NASDAQ: NVCN) between November 1, 2019 and October 27, 2020, inclusive (the "Class Period")....

ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Neovasc Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - NVCN

Neovasc Inc. (NVCN) CEO Fred Colen on Q3 2020 Results - Earnings Call Transcript

BENSALEM, Pa.--(BUSINESS WIRE)---- $NVCN #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Neovasc Inc. (NVCN) Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Neovasc Inc. (NVCN) Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York captioned Gonzalez v. Neovasc Inc., et al., (Case No. 1:20-cv-09313) on behalf of persons and entities that purchased or otherwise acquired Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) securities between November 1, 2019 and October 27, 2020, inclusive (the “Class Period”). Plaintiff pursues

NVCN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Neovasc Inc.

Neovasc (NVCN) delivered earnings and revenue surprises of 3.77% and 13.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Neovasc (NVCN) Reports Q3 Loss, Tops Revenue Estimates

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 5, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today reported financial results for the third quarter ended September 30, 2020.Third Quarter HighlightsGrew revenue 25% year-over-year in the quarter.Implants increased 50% year-over-year in the quarter including 100% growth in...

Neovasc Announces Third Quarter Financial Results

BENSALEM, Pa.--(BUSINESS WIRE)---- $NVCN #CLASSACTIONS--INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Neovasc, Inc (NVCN) on Behalf of Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Neovasc, Inc (NVCN) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $NVCN #CLASSACTION--Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Neovasc, Inc. (NVCN) on Behalf of Investors

Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Neovasc, Inc. (NVCN) on Behalf of Investors

Atlanta, Georgia--(Newsfile Corp. - November 3, 2020) - Holzer & Holzer, LLC is investigating whether Neovasc Inc. (NASDAQ: NVCN) ("Neovasc" or the "Company") complied with federal securities laws. On October 28, 2020, the Company announced that the FDA voted on its Neovasc Reducer and found against issuing a reasonable assurance of effectiveness and against whether the benefits outweigh the relative risks. The price of Neovasc's stock fell following the announcement. If you...

SHAREHOLDER ALERT: Investigation of Neovasc Announced by Holzer & Holzer, LLC

NEW YORK--(BUSINESS WIRE)-- #Investigation--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Neovasc, Inc. (NASDAQ: NVCN) on behalf of Neovasc stockholders. Our investigation concerns whether Neovasc has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On December 20, 2018, Neovasc filed a comprehensive Q-Sub submission to the FDA with all available evi

NEOVASC ALERT: Bragar Eagel & Squire, P.C. is Investigating Neovasc, Inc. on Behalf of Neovasc Stockholders and Encourages Investors to Contact the Firm

BENSALEM, Pa.--(BUSINESS WIRE)---- $NVCN #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Neovasc, Inc (NVCN) on Behalf of Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Neovasc, Inc (NVCN) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $NVCN #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Neovasc, Inc. (NVCN) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Neovasc, Inc. (NVCN) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $NVCN #NVCN--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Neovasc Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Neovasc Inc. and Encourages Investors with Losses to Contact the Firm

New York, New York--(Newsfile Corp. - October 31, 2020) - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Neovasc Inc. (NASDAQ: NVCN) resulting from allegations that Neovasc may have issued materially misleading business information to the investing public.On December 20, 2018, Neovasc filed a comprehensive Q-Sub submission to the FDA with all available evidence for its product Neovasc Reducer, including the prospective,...

Rosen, Trusted Investor Counsel, Announces Investigation of Securities Claims Against Neovasc Inc. - NVCN

LOS ANGELES--(BUSINESS WIRE)---- $NVCN #classaction--The Law Offices of Frank R. Cruz announces an investigation of Neovasc, Inc (“Neovasc” or the “Company”) (NASDAQ: NVCN) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. Neovasc's Reducer is a medical device that treats refractory angina by altering blood flow in the heart's circulatory system. In December 2018, the Company filed a Q-Sub submission

The Law Offices of Frank R. Cruz Announces Investigation of Neovasc, Inc (NVCN) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $NVCN #NVCN--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Neovasc Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Neovasc Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--In the fifth paragraph of release issued October 29, 2020 the date should read October 28, 2020 (instead of November 28, 2020). The updated release reads: NVCN EQUITY ALERT: ROSEN LAW FIRM ANNOUNCES INVESTIGATION OF SECURITIES CLAIMS AGAINST NEOVASC INC. – NVCN Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Neovasc Inc. (NASDAQ: NVCN) resulting from allegations that Neovasc may

CORRECTING and REPLACING NVCN Equity Alert: Rosen Law Firm Announces Investigation of Securities Claims Against Neovasc Inc. – NVCN

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Neovasc Inc. (NASDAQ: NVCN) resulting from allegations that Neovasc may have issued materially misleading business information to the investing public. On December 20, 2018, Neovasc filed a comprehensive Q-Sub submission to the FDA with all available evidence for its product Neovasc Reducer, including the prospective, multicenter, r

NVCN Equity Alert: Rosen Law Firm Announces Investigation of Securities Claims Against Neovasc Inc. – NVCN

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 28, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the United States Food and Drug Administration's (FDA's) Circulatory System Devices Advisory Panel voted 14 to 4 "in favor" that the Neovasc Reducer™ is safe when used as intended, and voted 1 to 17 "against" on the issue of a reasonable assurance of effectiveness. The third vote was 13 to 3...

Neovasc Announces FDA Advisory Panel Result on Neovasc Reducer(TM) Medical Device for the Treatment of Refractory Angina

VANCOUVER and MINNEAPOLIS, Oct. 28, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the United States Food and Drug Administration's (FDA's) Circulatory System Devices Advisory Panel voted 14 to 4 “in favor” that the Neovasc Reducer™ is safe when used as intended, and voted 1 to 17 "against" on the issue of a reasonable assurance of effectiveness. The third vote was 13 to 3 "against” (2 abstained) on whether the relative benefits outweighed the relative risks.

Neovasc Announces FDA Advisory Panel Result on Neovasc Reducer™ Medical Device for the Treatment of Refractory Angina

VANCOUVER and MINNEAPOLIS, Oct. 22, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (NASDAQ, TSX: NVCN) today announced that it will report financial results for the quarter ended September 30, 2020 after the market close on November 5, 2020.  Neovasc President and Chief Executive Officer Fred Colen, and Chief Financial Officer Chris Clark will host a conference call to review the company's results at 4:30 PM Eastern Time.

Neovasc to Report Third Quarter Financial Results on November 5, 2020

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 13, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that it will sponsor a symposium entitled "Unmet Need in Treating Patients With Refractory Angina" at the 2020 TCT Connect Online Conference, taking place October 14-18, 2020.The training session will be available via the TCT Connect e-satellite for registered participants beginning Friday, October 16, at 7 AM EDT. The session will...

Neovasc to Sponsor Symposium on Treating Patients with Refractory Angina at TCT Connect 2020

VANCOUVER and MINNEAPOLIS, Sept.  08, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced that its management team will be participating in the 22nd Annual H.C. Wainwright Global Investment Conference on September 14-16, 2020.  Fred Colen, Neovasc’s President and CEO, will present on September 15 at 3:30 pm EDT. 

Neovasc to Participate in H.C. Wainwright & Co.

VANCOUVER and MINNEAPOLIS, Aug.  17, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that Strul Medical Group LLC (“SMG”) exercised 501,000 of the remaining 1,149,910 common share purchase warrants (the “May Warrants”) issued pursuant to a Securities Purchase Agreement dated May 26, 2020 at an exercise price of US$2.634 per May Warrant for aggregate exercise proceeds to the Company of US$1,319,634.00 (the “Exercise Proceeds”). 

Neovasc Announces Partial Prepayment of Convertible Debenture

Vancouver, Canada, Aug.  12, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the “Offering”) priced at-the-market under the Nasdaq rules of an aggregate of 4,532,772 common shares at a purchase price of US$2.77575 per common share for aggregate gross proceeds to the Company of approximately US$12.6 million, before deducting placement agent’s fees and estimated expenses of the Offering payable by the Company.

News for Neovasc Stock (NVCN)